Editorial: achievements and unresolved questions in improving the pharmacokinetics of vedolizumab in adolescents with inflammatory bowel disease

Stephanie A. Vuijk, Lissy de Ridder*

*Corresponding author for this work

Research output: Contribution to journalEditorialAcademicpeer-review

1 Citation (Scopus)
Original languageEnglish
Pages (from-to)565-566
Number of pages2
JournalAlimentary Pharmacology and Therapeutics
Volume57
Issue number5
DOIs
Publication statusPublished - Mar 2023

Bibliographical note

Funding Information:
Declaration of personal interests: S.A. Vuijk: TISKids study was supported by ZonMw, Crocokids and an Investigator-Sponsored Research Award from Pfizer. L. de Ridder: Collaboration with Abbvie, Lilly, Takeda, Janssen and Pfizer. Grant from ZonMw, ECCO, Pfizer.

Funding Information:
S.A. Vuijk: TISKids study was supported by ZonMw, Crocokids and an Investigator‐Sponsored Research Award from Pfizer. L. de Ridder: Collaboration with Abbvie, Lilly, Takeda, Janssen and Pfizer. Grant from ZonMw, ECCO, Pfizer. Declaration of personal interests:

Cite this